Board changes
Updated : 09:01
16 September 2020
Board changes
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has been notified by John Hartup, the Senior Independent Non-Executive Director, that he will not stand for re-election at the Group's upcoming AGM which will take place on 26 November 2020.
The Nomination Committee is in the process of selecting a new independent Non-Executive Director and considering which Non-Executive Director will replace John as Senior Independent Director, Workforce Engagement Director and member of the Audit and Risk, Remuneration and Nomination Committees.
Peter Allen, Non-Executive Chairman, Clinigen, said:
"John has been on the Board for many years, both pre and post IPO and has been instrumental in the development and strengthening of the corporate governance framework through his tenure as both Senior Independent Director and more recently as the Director for Workforce Engagement. On behalf of the Board and everyone at Clinigen, I would like to thank him for his service and commitment and wish him well for the future."
- Ends -
For further information, please contact:
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Nick Keher, Group Chief Financial Officer Matt Parrish, Head of Investor Relations |
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker | Tel: +44 (0)20 7742 4000 |
James Mitford / Hemant Kapoor |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0)20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Instinctif Partners Adrian Duffield / Melanie Toyne Sewell / Phillip Marriage | Tel: +44 (0)20 7457 2020 Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.
Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.